Serrano-Oviedo L - Search Results

1

ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Arias-González L, Moreno-Gimeno I, del Campo AR, Serrano-Oviedo L, Valero ML, Esparís-Ogando A, de la Cruz-Morcillo MÁ, Melgar-Rojas P, García-Cano J, Cimas FJ, Hidalgo MJ, Prado A, Callejas-Valera JL, Nam-Cha SH, Giménez-Bachs JM, Salinas-Sánchez AS, Pandiella A, del Peso L, Sánchez-Prieto R. Arias-González L, et al. Neoplasia. 2013 Jun;15(6):649-59. doi: 10.1593/neo.121896. Neoplasia. 2013. PMID: 23730213 Free PMC article.

2

Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.

Salinas-Sánchez AS, Sánchez-Sánchez F, Donate-Moreno MJ, Rubio-del-Campo A, Gimenez-Bachs JM, Lorenzo-Romero JG, Serrano-Oviedo L, Escribano J. Salinas-Sánchez AS, et al. BJU Int. 2011 Jun;107(11):1825-32. doi: 10.1111/j.1464-410X.2010.09683.x. Epub 2010 Oct 13. BJU Int. 2011. PMID: 20942828

3

GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer.

Salinas-Sánchez AS, Sánchez-Sánchez F, Donate-Moreno MJ, Rubio-del-Campo A, Serrano-Oviedo L, Gimenez-Bachs JM, Martínez-Sanchiz C, Segura-Martín M, Escribano J. Salinas-Sánchez AS, et al. Urol Oncol. 2012 Nov-Dec;30(6):864-70. doi: 10.1016/j.urolonc.2010.10.001. Epub 2011 Apr 1. Urol Oncol. 2012. PMID: 21458313

4

[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma].

Salinas-Sánchez AS, Giménez-Bachs JM, Serrano-Oviedo L, Nam Cha S, Sánchez-Prieto R. Salinas-Sánchez AS, et al. Actas Urol Esp. 2012 Feb;36(2):99-103. doi: 10.1016/j.acuro.2011.07.013. Epub 2011 Sep 28. Actas Urol Esp. 2012. PMID: 21959062 Review. Spanish.

5

Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.

Giménez-Bachs JM, Salinas-Sánchez AS, Serrano-Oviedo L, Nam-Cha SH, Rubio-Del Campo A, Sánchez-Prieto R. Giménez-Bachs JM, et al. Scand J Urol Nephrol. 2012 Oct;46(5):358-64. doi: 10.3109/00365599.2012.685493. Epub 2012 May 10. Scand J Urol Nephrol. 2012. PMID: 22571179

6

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

Elorza A, Soro-Arnáiz I, Meléndez-Rodríguez F, Rodríguez-Vaello V, Marsboom G, de Cárcer G, Acosta-Iborra B, Albacete-Albacete L, Ordóñez A, Serrano-Oviedo L, Giménez-Bachs JM, Vara-Vega A, Salinas A, Sánchez-Prieto R, Martín del Río R, Sánchez-Madrid F, Malumbres M, Landázuri MO, Aragonés J. Elorza A, et al. Mol Cell. 2012 Dec 14;48(5):681-91. doi: 10.1016/j.molcel.2012.09.017. Epub 2012 Oct 25. Mol Cell. 2012. PMID: 23103253 Free article.

7

Abrogation of the p38 MAPK α signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity.

de la Cruz-Morcillo MA, García-Cano J, Arias-González L, García-Gil E, Artacho-Cordón F, Ríos-Arrabal S, Valero ML, Cimas FJ, Serrano-Oviedo L, Villas MV, Romero-Fernández J, Núñez MI, Sánchez-Prieto R. de la Cruz-Morcillo MA, et al. Cancer Lett. 2013 Jul 10;335(1):66-74. doi: 10.1016/j.canlet.2013.01.050. Epub 2013 Feb 8. Cancer Lett. 2013. PMID: 23403078

8

E1a promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization.

Valero ML, Cimas FJ, Arias L, Melgar-Rojas P, García E, Callejas-Valera JL, García-Cano J, Serrano-Oviedo L, de la Cruz-Morcillo MÁ, Sánchez-Pérez I, Sánchez-Prieto R. Valero ML, et al. Cell Cycle. 2014;13(1):52-61. doi: 10.4161/cc.26754. Epub 2013 Oct 11. Cell Cycle. 2014. PMID: 24196438 Free PMC article.

9

Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.

García-Cano J, Ambroise G, Pascual-Serra R, Carrión MC, Serrano-Oviedo L, Ortega-Muelas M, Cimas FJ, Sabater S, Ruiz-Hidalgo MJ, Sanchez Perez I, Mas A, Jalón FA, Vazquez A, Sánchez-Prieto R. García-Cano J, et al. Oncotarget. 2015 Jun 20;6(17):15551-65. doi: 10.18632/oncotarget.3902. Oncotarget. 2015. PMID: 26036632 Free PMC article.

10

MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.

Cimas FJ, Callejas-Valera JL, Pascual-Serra R, García-Cano J, Garcia-Gil E, De la Cruz-Morcillo MA, Ortega-Muelas M, Serrano-Oviedo L, Gutkind JS, Sánchez-Prieto R. Cimas FJ, et al. Oncotarget. 2015 Dec 29;6(42):44095-107. doi: 10.18632/oncotarget.6574. Oncotarget. 2015. PMID: 26689986 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page